Evidence map›Paper›PMID 32674283›Full record

ArticleCancers2020

Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype.

Sonja Heibl, Bettina Gisslinger, Eva Jäger, Agnes Barna, Michael Gurbisz, Maike Stegemann, Peter Bettelheim, Sigrid Machherndl-Spandl, Michael Pfeilstöcker, Thomas Nösslinger and 8 more

Abstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sonja HeiblDepartment of Internal Medicine IV, Hospital Wels-Grieskirchen, 4600 Wels, Austria.ORCID 0000-0001-8182-990X
Bettina GisslingerDivision of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
Eva JägerDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Agnes BarnaBlood Transfusion Service, Blood Transfusion Service for Upper Austria, Austrian Red Cross, 4020 Linz, Austria.
Michael GurbiszDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Maike StegemannDepartment of Internal Medicine V with Hematology, Oncology and Palliative Care, Hospital Hietzing, 1130 Vienna, Austria.
Peter BettelheimDepartment of Internal Medicine I with Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Barmherzige Schwestern-Elisabethinen, 4020 Linz, Austria.
Sigrid Machherndl-SpandlDepartment of Internal Medicine I with Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Barmherzige Schwestern-Elisabethinen, 4020 Linz, Austria.
Michael PfeilstöckerDepartment of Internal Medicine III, Hanusch Hospital, 1140 Vienna, Austria.
Thomas NösslingerDepartment of Internal Medicine III, Hanusch Hospital, 1140 Vienna, Austria.
Gökhan UyanikCenter for Medical Genetics, Hanusch Hospital, 1140 Vienna, Austria.
Gregor HoermannDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Reinhard StauderInternal Medicine V with Hematology and Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0002-8993-9561
Josef ThalerDepartment of Internal Medicine IV, Hospital Wels-Grieskirchen, 4600 Wels, Austria.
Rajko KusecSchool of Medicine, University of Zagreb, University Hospital Dubrava, 10000 Zagreb, Croatia.
Peter ValentDivision of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-0456-5095
Heinz GisslingerDivision of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
Klaus GeisslerDepartment of Internal Medicine V with Hematology, Oncology and Palliative Care, Hospital Hietzing, 1130 Vienna, Austria.

Funding

Austrian Science Fund (FWF) F4704-B20Gesellschaft zur Erforschung der Biologie und Therapie von Tumorkrankheiten ABCMML-112015
6 · The paper itself

Abstract

Patients with a myeloproliferative neoplasm (MPN) sometimes show a chronic myelomonocytic leukemia (CMML)-like phenotype but, according to the 2016 WHO classification, a documented history of an MPN excludes the diagnosis of CMML. Forty-one patients with an MPN (35 polycythemia vera (PV), 5 primary myelofibrosis, 1 essential thrombocythemia) and a CMML-like phenotype (MPN/CMML) were comprehensively characterized regarding clinical, hematologic, biologic and molecular features. The white blood cell counts in MPN/CMML patients were not different from CMML patients and PV patients. The hemoglobin values and platelet counts of these patients were higher than in CMML but lower than in PV, respectively. MPN/CMML patients showed myelomonocytic skewing, a typical in vitro feature of CMML but not of PV. The mutational landscape of MPN/CMML was not different from

Indexed as

chronic myelomonocytic leukemiamyeloproliferative neoplasmNGSprogenitor cellsprognosis

Identifiers

PMID32674283
PMCPMC7409251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.